Navigating MFN: Alan Crowther on What Pharma Brands Must Know Now

As the pharmaceutical industry grapples with the implications of the Most Favored Nation (MFN) Executive Order, Alan Crowther, General Manager of Global Pricing & Market Access Solutions, offers timely insights into what this directive means for brand strategy and innovation. 

In a recent interview with Pharmaceutical Executive, Crowther breaks down the latest MFN directive—a letter sent to 16 leading pharmaceutical firms urging collaboration with HHS to implement MFN pricing in the Medicaid channel. While the language is strong, the policy mechanism remains ambiguous, and the 60-day deadline adds urgency to the conversation. 

Crowther emphasizes that Medicaid MFN pricing, though less impactful than broader MFN policies, still demands attention. With Medicaid representing less than 10% of pharmaceutical spend and rebates exceeding 50%, the risk of spillover to other pricing channels is reduced—but not eliminated. He warns that launching products without a risk mitigation plan is akin to “buying a home without insurance in a fire zone”. 

For a deeper dive into Crowther’s perspective and what pharma brands should be doing now, read the full article on Pharmaceutical Executive here.  

Connect With An Expert!